John Sharkey, NP
Adult Health · Greenville, SCNPI 1336532456
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations.
Across 271 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$623
- Akebia Therapeutics Inc$419
- Bayer$377
- Novartis$372
- Boehringer Ingelheim$312
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,46798%
- Education$1052%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 62 | $1,262 |
| AstraZeneca(2 entities) | 37 | $623 |
| Akebia Therapeutics Inc | 18 | $419 |
| Bayer | 23 | $377 |
| Novartis | 15 | $372 |
| Boehringer Ingelheim | 13 | $312 |
| Calliditas Therapeutics US Inc. | 12 | $287 |
| Mallinckrodt Hospital Products Inc. | 9 | $265 |
| Otsuka America Pharmaceutical, Inc. | 13 | $230 |
| Vifor Pharma, Inc. | 12 | $230 |
| Fresenius USA Marketing, Inc. | 8 | $140 |
| OPKO Pharmaceuticals, LLC | 8 | $136 |
| GSK | 6 | $124 |
| ANI Pharmaceuticals, Inc. | 5 | $121 |
| Regeneron Healthcare Solutions, Inc. | 5 | $103 |
| Nxstage Medical, Inc. | 1 | $99 |
| Novo Nordisk | 4 | $82 |
| Aurinia Pharma U.S., Inc. | 4 | $72 |
| Travere Therapeutics, Inc. | 4 | $70 |
| Daiichi Sankyo Inc. | 3 | $67 |
| Ardelyx, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $33 |
| Nuwellis, Inc. | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Sanofi | 1 | $18 |
How this compares
$5,572 in reported general payments places this provider in the 85th percentile of 292 adult health providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 52 | $49,774 |
| JardianceEmpagliflozin | 32 | $31,953 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $21,091 |
| AuryxiaFerric Citrate | 14 | $17,064 |
| EliquisApixaban | 13 | $10,805 |
| KerendiaFinerenone | 14 | $9,275 |
| Sevelamer Carbonate | 32 | $4,416 |
| Midodrine Hcl | 24 | $1,192 |
| Torsemide | 31 | $796 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $545 |
| Amlodipine Besylate | 88 | $502 |
| Allopurinol | 62 | $463 |
| Gabapentin | 41 | $425 |
| Carvedilol | 81 | $392 |
| Lisinopril | 53 | $339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $623 | $70,86563 claims |
| Boehringer IngelheimJardiance | $312 | $31,95332 claims |
| Akebia Therapeutics IncAuryxia | $419 | $17,06414 claims |
| BayerKerendia | $377 | $9,27514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 292 adult health providers in South Carolina.
Other adult health in Greenville
- Karen RobertsonGreenville$69K
- Jessica RiceGreenville$15K
- Sheri MorrisGreenville$8K
- James McKenzieGreenville$8K
- Gary SzetoGreenville$6K
- Sarah BaranskiGreenville$5K
- Brandi RuffoGreenville$4K
- Lynn CurryGreenville$4K
- Christine FranzeseTega Cay$30K
- Michelle PriceCharleston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.